3 news items
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
ARVN
NVS
7 May 24
and other product candidates on current timelines or at all; the satisfaction or waiver of the closing conditions set forth in the license agreement
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
ARVN
ATOS
ICCM
30 Apr 24
and physician satisfaction and 96.3% recurrence-free rate for its ProSense® System, a minimally-invasive cryoablation technology that destroys tumors
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
ARVN
ATOS
ICCM
30 Apr 24
and physician satisfaction and 96.3% recurrence-free rate for its ProSense® System, a minimally-invasive cryoablation technology that destroys
- Prev
- 1
- Next